Overview Dividends

(CL) Colgate-Palmolive - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1941621039

Toothpaste, Soap, Shampoo, Detergent, Pet Food

Household Products
Market Cap in USD: 63,995m

IPO / Inception: 1977-01-03
Return 12m vs S&P 500: -26.3%

EPS (Earnings per Share)

EPS CAGR: 3.84%
EPS Trend: 88.8%

Last SUE: 0.00
Qual. Beats: 0

Revenue

Rev. CAGR: 4.16%
Rev. Trend: 91.5%

Last SUE: 0.05
Qual. Beats: 0

Dividends

Dividend Yield	2.57%
Yield on Cost 5y	2.71%
Yield CAGR 5y	3.14%
Payout Consistency	96.1%
Payout Ratio	56.4%

Risk via 10d forecast
Volatility	19.5%
Value at Risk 5%th	31.9%
Relative Tail Risk	-0.67%

Reward TTM
Sharpe Ratio	-0.82
Alpha	-18.34
CAGR/Max DD	0.12

Character TTM
Hurst Exponent	0.410
Beta	0.044
Beta Downside	-0.022

Drawdowns 3y
Max DD	29.05%
Mean DD	9.29%
Median DD	7.61%

Description: CL Colgate-Palmolive September 26, 2025

Colgate-Palmolive (NYSE: CL) is a U.S.–based consumer-goods company that operates two primary segments: Oral, Personal & Home Care and Pet Nutrition. The first segment sells a broad array of daily-use products-including toothpaste, soaps, shampoos, deodorants, and household cleaners-under well-known brands such as Colgate, Palmolive, Tom’s of Maine, and Irish Spring, reaching traditional brick-and-mortar retailers, e-commerce platforms, wholesalers, dentists, and skin-health professionals.

The Pet Nutrition segment is focused on Hill’s Science Diet (everyday nutrition) and Hill’s Prescription Diet (therapeutic formulas) and distributes primarily through pet-supply chains, veterinary clinics, and online retailers. Both segments benefit from the company’s global footprint, with sales spanning the United States and more than 200 international markets.

Key recent metrics (FY 2023) show net sales of roughly $17.4 billion, an operating margin of about 15 %, and a dividend yield near 2.5 %. The oral-care market is a $50 billion defensive niche, while pet-nutrition is growing at an estimated 5 % CAGR, driven by increasing pet-ownership rates and premiumization trends.

Sector drivers that materially affect CL’s performance include (1) consumer-price-inflation pressure on discretionary spend, (2) currency-exchange volatility given the company’s exposure to emerging-market earnings, and (3) the ongoing shift toward e-commerce, which has accelerated the adoption of direct-to-consumer channels for both oral-care and pet-nutrition products.

For a data-rich, forward-looking analysis of how these dynamics translate into valuation risk and upside, you may find ValueRay’s platform worth a deeper look.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (2.91b TTM) > 0 and > 6% of Revenue (6% = 1.21b TTM)

FCFTA 0.20 (>2.0%) and ΔFCFTA -0.61pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -2.27% (prev 1.20%; Δ -3.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 4.01b > Net Income 2.91b (YES >=105%, WARN >=100%)

Net Debt (7.14b) to EBITDA (4.81b) ratio: 1.48 <= 3.0 (WARN <= 3.5)

Current Ratio 0.93 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (810.2m) change vs 12m ago -1.50% (target <= -2.0% for YES)

Gross Margin 60.15% (prev 60.29%; Δ -0.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 117.2% (prev 119.9%; Δ -2.64pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 15.57 (EBITDA TTM 4.81b / Interest Expense TTM 270.0m) >= 6 (WARN >= 3)

Altman Z'' 8.10

(A) -0.03 = (Total Current Assets 6.04b - Total Current Liabilities 6.50b) / Total Assets 17.51b

(B) 1.54 = Retained Earnings (Balance) 27.05b / Total Assets 17.51b

warn (B) unusual magnitude: 1.54 — check mapping/units

(D) 1.51 = Book Value of Equity 24.63b / Total Liabilities 16.27b

Total Rating: 8.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 81.99

1. Piotroski 5.50pt

2. FCF Yield 4.84%

3. FCF Margin 17.13%

4. Debt/Equity 9.84

5. Debt/Ebitda 1.48

6. ROIC - WACC (= 31.02)%

7. RoE 545.1%

8. Rev. Trend 91.50%

9. EPS Trend 88.79%

What is the price of CL shares?

As of November 28, 2025, the stock is trading at USD 80.04 with a total of 4,049,371 shares traded.
Over the past week, the price has changed by +1.50%, over one month by +2.84%, over three months by -4.59% and over the past year by -15.28%.

Is CL a buy, sell or hold?

Colgate-Palmolive has received a consensus analysts rating of 3.77. Therefor, it is recommend to hold CL.

Strong Buy: 7
Buy: 6
Hold: 7
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the CL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	87.2	9%
Analysts Target Price	87.2	9%
ValueRay Target Price	78.4	-2.1%

CL Fundamental Data Overview November 26, 2025

Market Cap USD = 63.99b (63.99b USD * 1.0 USD.USD)
P/E Trailing = 22.1793
P/E Forward = 20.79
P/S = 3.1843
P/B = 76.2089
P/EG = 1.6778
Beta = 0.3
Revenue TTM = 20.10b USD
EBIT TTM = 4.20b USD
EBITDA TTM = 4.81b USD
Long Term Debt = 7.31b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 8.42b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.14b USD (from netDebt column, last quarter)
Enterprise Value = 71.13b USD (63.99b + Debt 8.42b - CCE 1.28b)
Interest Coverage Ratio = 15.57 (Ebit TTM 4.20b / Interest Expense TTM 270.0m)
FCF Yield = 4.84% (FCF TTM 3.44b / Enterprise Value 71.13b)
FCF Margin = 17.13% (FCF TTM 3.44b / Revenue TTM 20.10b)
Net Margin = 14.47% (Net Income TTM 2.91b / Revenue TTM 20.10b)
Gross Margin = 60.15% ((Revenue TTM 20.10b - Cost of Revenue TTM 8.01b) / Revenue TTM)
Gross Margin QoQ = 59.42% (prev 60.06%)
Tobins Q-Ratio = 4.06 (Enterprise Value 71.13b / Total Assets 17.51b)
Interest Expense / Debt = 0.80% (Interest Expense 67.0m / Debt 8.42b)
Taxrate = 22.78% (226.0m / 992.0m)
NOPAT = 3.25b (EBIT 4.20b * (1 - 22.78%))
Current Ratio = 0.93 (Total Current Assets 6.04b / Total Current Liabilities 6.50b)
Debt / Equity = 9.84 (Debt 8.42b / totalStockholderEquity, last quarter 856.0m)
Debt / EBITDA = 1.48 (Net Debt 7.14b / EBITDA 4.81b)
Debt / FCF = 2.07 (Net Debt 7.14b / FCF TTM 3.44b)
Total Stockholder Equity = 533.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.60% (Net Income 2.91b / Total Assets 17.51b)
RoE = 545.1% (Net Income TTM 2.91b / Total Stockholder Equity 533.2m)
RoCE = 53.63% (EBIT 4.20b / Capital Employed (Equity 533.2m + L.T.Debt 7.31b))
RoIC = 36.55% (NOPAT 3.25b / Invested Capital 8.88b)
WACC = 5.53% (E(63.99b)/V(72.41b) * Re(6.18%) + D(8.42b)/V(72.41b) * Rd(0.80%) * (1-Tc(0.23)))
Discount Rate = 6.18% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.91%
[DCF Debug] Terminal Value 79.70% ; FCFE base≈3.43b ; Y1≈3.79b ; Y5≈4.93b
Fair Price DCF = 106.4 (DCF Value 85.73b / Shares Outstanding 806.1m; 5y FCF grow 12.34% → 3.0% )
EPS Correlation: 88.79 | EPS CAGR: 3.84% | SUE: 0.0 | # QB: 0
Revenue Correlation: 91.50 | Revenue CAGR: 4.16% | SUE: 0.05 | # QB: 0

Additional Sources for CL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle